Navigation Links
Harmless human virus may be able to boost the effects of chemotherapy
Date:4/3/2012

A naturally-occurring harmless human virus may be able to boost the effects of two standard chemotherapy drugs in some cancer patients, according to early stage trial data published in Clinical Cancer Research.

The paper titled: Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies with first author Eleni M. Karapanagiotou from the ICR and The Royal Marsden was published in the print edition of Clinical Cancer Research on April 1.

RT3D, trade name Reolysin, is a new drug developed by Oncolytics Biotech Inc with preclinical and clinical studies conducted at The Institute of Cancer Research (ICR) and The Royal Marsden Hospital. It is based on a virus (reovirus type 3 Dearing) that is found in almost all adults' respiratory and gastrointestinal tracts without causing any symptoms.

RT3D has the ability to grow in and kill certain types of cancer cells, but does not grow in normal cells.

Previous trials injecting patients with the virus on its own showed limited effectiveness, but the team found that RT3D appeared to magnify the effects of platin and taxane-based chemotherapy on tumour cells.

Dr Kevin Harrington and colleagues in Leeds therefore started a clinical trial testing intravenous RT3D in combination with chemotherapeutics carboplatin and paclitaxel in 31 patients with advanced cancers who had stopped responding to standard treatments.

An initial Phase I study was carried out in patients with a range of advanced cancers, which showed the drug combination was safe. Side-effects were found to be generally mild, and consistent with chemotherapy alone.

Patients with head and neck cancers were found to have the best responses, so a Phase II expansion study at The Royal Marsden Hospital, London, and St James's Hospital, Leeds, was therefore targeted to patients with these types of cancers.

Cancers shrank for about one third of the patients who could be evaluated, and disease stabilised for a further third. For one patient, all signs of their cancer disappeared.

"We saw really very impressive response rates in these patients. These are patients whose cancers had grown despite a great deal of previous treatment, including platinum-based chemotherapy for many," Dr Harrington, Leader of the ICR's Targeted Therapy Team and Consultant Oncologist at The Royal Marsden, said. "Under those circumstances, we'd expect that the average response rate to chemotherapy alone might be as low as single digits figures and the average survival would be somewhere between three to four months. In our Phase I/II study we show this had been prolonged to an average of seven months, albeit not in a randomised trial."

"Based on the results of this study we've now started recruiting patients with advanced head and neck cancer to a randomised Phase III trial, in which all patients will receive chemotherapy and half will receive Reolysin as well. We are extremely excited about this progress."

The study also found the virus was not shed after treatment. This means people could be given the drug as outpatients as no risk was found that they could transmit the virus to others.


'/>"/>

Contact: Janet Vasquez
jvasquez@investorrelationsgroup.com
212-825-3210
Oncolytics Biotech Inc.
Source:Eurekalert

Related biology news :

1. Swiss Institute of Bioinformatics celebrates 10th birthday by presenting major gifts to human health
2. Scientists identify novel inhibitor of human microRNA
3. During exercise, the human brain shifts into high gear on alternative energy
4. Complete Genomics launches, becomes worlds first large-scale human genome sequencing company
5. Research shows Brazilian acai berry antioxidants absorbed by human body
6. Study: Bird diversity lessens human exposure to West Nile Virus
7. Human Microbiome Project awards funds for technology development, data analysis and ethical research
8. TheVisualMD.com launches new animated 3-D views of human body in action
9. Gene with probable role in human susceptibility to pulmonary tuberculosis identified
10. The American Society of Human Genetics hosts 58th Annual Meeting in Philadelphia
11. Genetic based human diseases are an ancient evolutionary legacy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... Optimove , provider of the ... as 1-800-Flowers and AdoreMe, today announced two new ... Using Optimove,s machine learning algorithms, these features allow ... recommendations to their customers based not just on ... intent drawn from a complex web of data ...
(Date:3/20/2017)... At this year,s CeBIT Chancellor Dr. Angela Merkel visited the ... the DERMALOG stand together with the Japanese Prime Minster Shinzo Abe. ... largest German biometrics company the two government leaders could see the three ... as DERMALOG´s multi-biometrics system.   Continue Reading ... ...
(Date:3/16/2017)... - Against identity fraud with DERMALOG solutions "Made in Germany "  ... ... multi-biometric solutions provide a crucial contribution against identity fraud. (PRNewsFoto/Dermalog Identification Systems) ... Used combined in one project, multi-biometric solutions provide a crucial contribution against identity ... ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... ... 2017 , ... Ellen Matloff, president and CEO of My ... a 2017 Women of Innovation® finalist. Matloff will be among several women to ... dinner recognizes women accomplished in science, technology, engineering and math (STEM), along with ...
(Date:3/23/2017)... , March 23, 2017 NetworkNewsWire Editorial ... ... putting significant strain on health care systems, in terms of ... rises, so too does the development of innovative and efficient ... effects. Among the many types of cancer treatments, a growing ...
(Date:3/23/2017)... 23, 2017  Agriculture technology company Cool Planet has ... note conversion to commercialize its Cool Terra and Cool ... developing products that are simultaneously profitable as well as ... last 18 months. This latest round of funding was ... The company,s primary product, Cool Terra, ...
(Date:3/23/2017)... ... March 23, 2017 , ... Advanced Polymer Monitoring ... of Dr. Sigmund “Sig” Floyd as Vice President ? Global Business Development. Dr. ... activities. , “Dr. Floyd’s career has spanned 30 years in the chemicals and ...
Breaking Biology Technology: